Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Multiple myeloma (MM) requires effective first-relapse therapies, especially when autologous stem cell transplant (ASCT) is considered.
• Prior treatment with lenalidomide-bortezomib-dexamethasone (RVD) followed by lenalidomide maintenance is common.
• The role of subsequent therapies after RVD, with or without prior ASCT, needs evaluation.

Purpose of the Study:

• To assess the efficacy and safety of weekly oral pomalidomide-cyclophosphamide-dexamethasone (PCD) in multiple myeloma patients experiencing their first relapse after RVD therapy.
• To determine the response rate after four cycles of PCD and evaluate the feasibility of subsequent ASCT.

Main Methods:

• A multicenter, phase 2 trial involving patients with multiple myeloma in first relapse after RVD treatment.
• Patients received four oral cycles of PCD, with subsequent treatment tailored based on response and prior ASCT status.
• Response was evaluated by partial remission or better after initial PCD cycles; toxicity was monitored.

Main Results:

• An overall response rate of 85% (including complete remission, very good partial remission, and partial remission) was observed after four PCD cycles.
• Ninety-four percent of eligible patients in one arm proceeded to autologous stem cell transplant (ASCT) as planned.
• The toxicity profile was predominantly hematologic and manageable.

Conclusions:

• Weekly oral PCD is an effective first-line salvage therapy for multiple myeloma patients relapsing after RVD.
• PCD facilitates high rates of ASCT in eligible patients, supporting its role in treatment sequencing.
• The PCD regimen demonstrates a manageable safety profile in this patient population.